Skip to main content
v2026.11,986 entries · CC-BY 4.0

IITP (CASRAI)

Investigator-Initiated Trial Management Certification: IITP (CASRAI)

Examined CASRAI credential for the sponsor side of investigator-initiated trials: IND and IDE decisions, safety reporting, monitoring, multi-site work, records and product supply.

LevelProfessionalIITIITP (CASRAI)
4 h
Nominal
Self-paced study
8
Lessons
Self-paced
8
Domains
Exam blueprint
75
Exam items
Per attempt
70%
Pass mark
Fixed, uncurved
90
Retake wait
Days
3 yr
Valid for
From the pass

What you earn

The credential itself

Pass the examination and CASRAI issues this certificate and the post-nominal IITP (CASRAI), signed by the Programme Director, valid for 3 years, and checkable by anyone from the verification code on its face.

Specimen. Issued as a signed PDF and as a machine-readable Open Badge; the holder and code shown are illustrative.
How it appears on your CV

Certifications

IITP (CASRAI) — Investigator-Initiated Trial Management, Professional

CASRAI·Issued Mar 2026·Credential ID CASRAI-IIT-2026-O8OR4K

casrai.org/verify/CASRAI-IIT-2026-O8OR4K

Every certificate is issued under the signature of Dr. Diana Nieves Castro, MD, Programme Director of CASRAI Certification, who sets the syllabus, blueprint and pass mark for this credential.

It certifies that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published on this page — and anyone can confirm it from the verification code, without an account and without contacting us.

About this credential

What it covers

Investigator-Initiated Trial Management — Professional is an examined CASRAI credential for the people who carry, or support, the sponsor side of an investigator-initiated clinical trial. Holders use the designation IITP (CASRAI). The course is built on US regulation: 21 CFR Parts 50, 54, 56, 312 and 812, 42 CFR Part 11 and, for HHS-supported research, 45 CFR Part 46. The EU and UK sponsor rules appear only as a comparison.

Who it is for

  • Clinical trials office and regulatory staff who support investigator-held INDs and IDEs
  • Coordinating-centre administrators for multi-site academic trials
  • Research pharmacy staff with responsibility for investigator-initiated studies
  • Departmental administrators who support a sponsor-investigator
  • Sponsor-investigators who want a structured, examined grounding in the sponsor half of their role

The course assumes you already know GCP and the basics of an IND or IDE submission. It teaches the obligations that attach once an investigator or institution takes on the sponsor role.

What you will be able to do

  • Decide whether a planned study needs an IND or IDE, write the determination with reasons, and know when to ask FDA for advice
  • Recognise the routes into the sponsor role that people take without meaning to, including expanded access and the institution-as-sponsor rule
  • Map every sponsor and investigator obligation in a study to named people, and design a control wherever one person holds both sides
  • Draft or review a written transfer of obligations and identify what it has not transferred
  • Decide whether an investigator’s brochure is required, and set up the reference against which expectedness is judged when it is not
  • Apply the drug and device safety-reporting thresholds and clocks, including the calendar-day and working-day difference, and evidence distribution to every participating investigator
  • Design monitoring that a single academic sponsor can actually carry out and evidence, and tell sponsor monitoring, data and safety monitoring and IRB continuing review apart
  • Run the multi-site obligations: investigator statements and agreements, new-investigator amendments, IRB arrangements, and ClinicalTrials.gov registration, results and responsible-party designation
  • Keep sponsor records separate from site records, apply the correct retention trigger, and prepare for an inspection of the sponsor’s activities
  • Read an industry supply agreement for the terms that decide feasibility, and apply the labelling, charging and disposition rules for investigational product

Modules

  1. Deciding whether to become a sponsor: IND and IDE applicability
  2. The dual role: where the sponsor and investigator duties conflict
  3. Protocol, investigator’s brochure and the device investigational plan
  4. Sponsor safety reporting: drug and device clocks
  5. Monitoring, data and safety monitoring, and the sponsor’s monitoring duty
  6. Multi-site trials: the coordinating centre, IRB arrangements and registration
  7. Sponsor records, retention and inspection readiness
  8. Product supply, charging, industry agreements and institutional infrastructure

The exam

  • 75 scored multiple-choice questions per attempt, drawn from a larger bank in proportion to the published domain weights
  • Most questions are short scenarios that ask you to apply or analyse the rules; a smaller share test recall
  • Every question that tests a US rule names the jurisdiction and, where you would look it up in practice, the citation
  • Pass mark: 70%
  • Must be finished within 4 hours of starting.
  • You must complete every lesson before you can start the exam
  • If you do not pass, you can retake the exam after 90 days

Eligibility

There is no Foundation tier in this subject: the role is not an entry-level one. At checkout you confirm that you meet one of these routes; CASRAI does not ask for documents:

  • Regulatory route: you hold the CASRAI Regulatory Affairs for Research Sites credential (RARF or RARP), or you have equivalent working knowledge of 21 CFR Parts 50, 54, 56, 312 and 812.
  • Experience route: you have at least two years of substantial work supporting an investigator-initiated IND or IDE on the sponsor side, for example in a clinical trials office, as a regulatory manager, as a coordinating-centre administrator, in a research pharmacy with responsibility for investigator-initiated studies, or as a sponsor-investigator’s departmental administrator. Investigator-side clinical coordination on its own does not count.

What the credential is, and what it is not

  • It is an examined credential issued by CASRAI. Each certificate can be verified with CASRAI.
  • It is not accredited, and it carries no CE, CME or CEU credit.
  • It does not meet any statutory, funder, sponsor or institutional training requirement.
  • It is not endorsed by FDA, OHRP or any other regulator, funder or professional body.
  • It gives no regulatory authority. Holding it does not entitle anyone to decide alone that a study is exempt from the IND or IDE requirements, that a device is not a significant risk device, or that a monitoring plan is adequate. Those decisions still need the institutional review, IRB review and, where it applies, FDA review that the regulations provide for.

Validity and renewal

An IITP (CASRAI) certificate is valid for 3 years from the date you pass. To renew it, you pass the current version of the exam again.

Price

US$279, paid once. The price covers the eight-module course and the exam, and your course access does not expire.

Body of knowledge

Exam blueprint

The exam is assembled to these weights on every attempt. They are published before purchase because a blueprint you cannot see is not a blueprint.

Domains and weights8 domains · 75 scored items
DomainWeight
Deciding whether to become a sponsorD1
14%11 items
The dual role: where sponsor and investigator duties conflictD2
16%12 items
Protocol, investigator's brochure and the device investigational planD3
12%9 items
Sponsor safety reporting for drug and device studiesD4
14%11 items
Sponsor monitoring and data and safety monitoringD5
14%11 items
Multi-site trials, IRB arrangements and ClinicalTrials.gov registrationD6
10%7 items
Sponsor records, retention and inspectionD7
10%7 items
Product supply, labelling, charging, agreements and institutional infrastructureD8
10%7 items
Total100%

Every attempt has this many items from each domain. The items themselves are drawn at random from the bank within those fixed per-domain quotas, so no two attempts are the same paper.

Syllabus

Syllabus: 8 lessons, 4 hours

Every lesson and every learning outcome is listed. The lesson bodies open on enrolment, and the exam opens once every lesson is marked complete.

8 lessons · 4.3 h

Lesson material opens once you are enrolled. The full syllabus and every learning outcome are shown here so you can judge the coverage before you pay.

  1. Lesson 1

    Module 1

    1 lesson · 45 min

    1. Locked.Deciding whether to become a sponsor: IND and IDE applicability45 min · Locked

      On completion you will be able to

      • Determine, for a described study, whether 21 CFR 312.2 or 812.2 requires an IND or IDE, and write the determination with its reasons
      • Distinguish the 312.2(b)(1) exemption from the 312.2(d) practice-of-medicine provision and explain the difference to a clinician
      • Classify a described device under the four limbs of 812.3(m) and state the consequence of an IRB significant-risk determination
      • Identify when an individual or institution becomes a sponsor or sponsor-investigator, including through expanded access under 312.305(c)
      • List the sponsor obligations an institution accepts before a Form FDA 1571 is signed
  2. Lesson 2

    Module 2

    1 lesson · 30 min

    1. Locked.The dual role: where the sponsor and investigator duties conflict30 min · Locked

      On completion you will be able to

      • Map each sponsor and investigator obligation in a described study to a named person and identify every point where one person holds both
      • Design and justify a control for each of the six dual-role conflicts
      • Apply 312.52 to a draft transfer and identify each obligation that has not been transferred
      • Distinguish tasks that may be delegated from commitments that are personal, citing the regulatory basis for each
      • Determine what financial interests must be reported and recorded under 312.64(d), 312.57(b) and Part 54 for a described family situation
  3. Lesson 3

    Module 3

    1 lesson · 30 min

    1. Locked.Protocol, investigator’s brochure and the device investigational plan30 min · Locked

      On completion you will be able to

      • Review a protocol against 312.23(a)(6)(iii) at a level of detail proportionate to its phase
      • Determine whether an investigator's brochure is required and, where it is not, organise the IND risk information that expectedness will be judged against
      • State what 312.55(b) still requires of a sponsor-investigator and choose an appropriate means of meeting it
      • Check a device investigational plan against 812.25 and classify a proposed plan change under 812.35(a)
      • Distinguish regulatory protocol requirements from publication guidelines and from FDA guidance
  4. Lesson 4

    Module 4

    1 lesson · 30 min

    1. Locked.Sponsor safety reporting: drug and device clocks30 min · Locked

      On completion you will be able to

      • Apply the 312.32(c)(1)(i) threshold to a described event and state whether it is reportable
      • Identify which drug or device clock applies, the event that starts it and its unit (calendar or working days)
      • Design and evidence distribution of IND safety reports to all participating investigators
      • Sequence the evaluation, reporting and termination duties that follow an unanticipated adverse device effect
      • Reconcile a year's IND safety reports against the 312.33 annual report
  5. Lesson 5

    Module 5

    1 lesson · 30 min

    1. Locked.Monitoring, data and safety monitoring, and the sponsor’s monitoring duty30 min · Locked

      On completion you will be able to

      • Write a monitoring plan for a single-site academic trial that states which obligation each element meets
      • Determine whether a DSMB is required for a described study and, where it is a design choice, specify one to a defensible standard
      • Evaluate whether a described arrangement can demonstrate the sponsor's monitoring duty, including its independence
      • Classify a described activity as sponsor monitoring, data and safety monitoring or IRB continuing review
  6. Lesson 6

    Module 6

    1 lesson · 30 min

    1. Locked.Multi-site trials: the coordinating centre, IRB arrangements and registration30 min · Locked

      On completion you will be able to

      • Obtain and check the correct investigator instrument for a drug or device study
      • Identify which sponsor obligations become harder at more than one site and assign each to a coordinating-centre function
      • Determine whether a single-IRB requirement applies to a described multi-site study, and from which instrument
      • Determine whether a trial is an applicable clinical trial and set the registration and results deadlines
      • Make, maintain and withdraw a responsible-party designation under 42 CFR 11.4(c)
  7. Lesson 7

    Module 7

    1 lesson · 30 min

    1. Locked.Sponsor records, retention and inspection readiness30 min · Locked

      On completion you will be able to

      • Distinguish the records a sponsor must hold from those an investigator must hold, and design a file structure that keeps both
      • Apply the E6(R3) essentiality criteria to described records
      • Apply the correct drug or device retention trigger and explain why neither is a fixed number of years
      • Prepare an institution for an inspection of its activities as sponsor
  8. Lesson 8

    Module 8

    1 lesson · 30 min

    1. Locked.Product supply, charging, industry agreements and institutional infrastructure30 min · Locked

      On completion you will be able to

      • Design investigational product supply, labelling, accountability and disposition for an academic sponsor
      • Identify the statutory limits on supplying a trial from an institutional compounding pharmacy and decide when to escalate
      • Read a supply agreement and identify the clauses that decide regulatory feasibility and control
      • Apply 312.8 to a proposal to charge for investigational product
      • Specify the infrastructure an institution needs to run investigator-initiated trials and identify what is missing in a described programme

Assessment

How the exam works

The exam is closed-book and multiple choice. Each attempt draws a fresh form to the domain weights above, so no two attempts are the same paper and no answer key circulates. The pass mark is 70% and is fixed — there is no curve, no quota and no adjustment by cohort.

Scoring is immediate. Pass, and every item is reviewed with the option you chose, the correct option and its rationale. If you do not pass, you see your overall score and your score per domain (smaller domains are grouped together); which items you missed, and their answers, are held back so your resit is still a real assessment. A failed attempt may be retaken after 90 days. The wait exists so a retake is a second attempt at the material rather than a second attempt at remembering the paper.

The exam opens once you have marked every lesson of the course complete. Forms are assembled to the blueprint above or not at all: where a domain cannot yet be sampled to that standard, the exam declines to start rather than issue an unbalanced paper. Your material and progress are never affected, and there is no time limit on when you sit.

Passing candidates are issued a certificate with a verification code, valid for 3 years from the date of the pass. Anyone can check that code on our public verification page without an account and without contacting us. To renew, pass the current examination again: renewal opens 180 days before the certificate expires, and a pass issues a renewed certificate valid for a further 3 years from that date.

Certifying authority

Signed by Dr. Diana Nieves Castro, MD

CASRAI’s certification programme is academically and medically directed by Dr. Diana Nieves Castro, MD, Programme Director, who sets the syllabus and blueprint for this credential and signs every certificate issued under it.

CASRAI has maintained the terminology and reporting standards of research administration for over a decade. It assumed leadership of the CRediT contributor-roles taxonomy in 2014 and carried it through to adoption as ANSI/NISO Z39.104-2022, now in use by publishers, funders and institutions worldwide. This examination is drawn from that body of work.

What the credential certifies: that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published above. It is valid for 3 years, and anyone can check it from the verification code on its face.

Common questions

Investigator-Initiated Trial Management Certification: IITP (CASRAI): common questions

What is an investigator-initiated trial?

An investigator-initiated trial (IIT) is a clinical study that an investigator or academic institution starts and runs itself, rather than one a drug or device company sponsors. When an individual both initiates and conducts the investigation, US regulation calls that person a sponsor-investigator: 21 CFR 312.3 defines the role for drugs and 21 CFR 812.3(o) for devices, and both say the person carries the obligations of a sponsor and of an investigator. An organisation that uses its own employees to conduct an investigation it initiated is a sponsor, not a sponsor-investigator.

What is the difference between a sponsor and an investigator in clinical trials?

Under 21 CFR 312.3, the sponsor takes responsibility for and initiates a clinical investigation, and does not actually conduct it unless it is a sponsor-investigator. The investigator is the individual who actually conducts the investigation, under whose immediate direction the drug is administered or dispensed. In an investigator-initiated trial one individual can hold both roles, and then carries the requirements of both.

What are the responsibilities of a sponsor in a clinical trial?

For US drug studies, 21 CFR 312.50 makes sponsors responsible for selecting qualified investigators, giving them the information they need, ensuring proper monitoring, keeping the investigation in line with the investigational plan and protocols in the IND, maintaining an effective IND, and promptly informing FDA and all participating investigators of significant new adverse effects or risks. Further sponsor duties are set out elsewhere in Part 312. The IITP course covers these duties in eight modules, from deciding whether to become a sponsor to safety reporting, monitoring, multi-site trials, records and inspection readiness.

What is the difference between investigator-initiated and sponsor-initiated trials?

Under 21 CFR 312.3, a sponsor can be an individual, a pharmaceutical company, a governmental agency, an academic institution or another organisation. In an industry-sponsored trial the company is the sponsor; in an investigator-initiated trial the investigator or the academic institution takes on the sponsor role and its obligations. IITP (CASRAI) is a US$279 course of 8 lessons and 4 study hours, ending in a 75-item online multiple-choice exam with a 70% pass mark.

What are the roles and responsibilities of an investigator?

Under 21 CFR 312.60, an investigator must make sure the investigation follows the signed investigator statement, the investigational plan and the applicable regulations, protect the rights, safety and welfare of the subjects in their care, control the drugs under investigation, and obtain informed consent under 21 CFR Part 50. A sponsor-investigator has these duties plus the sponsor's. IITP examines the sponsor side of that role.

What qualifications should a sponsor ensure an investigator has before selecting them to take part in a clinical trial?

21 CFR 312.53(a) says a sponsor may select only investigators qualified by training and experience as appropriate experts to investigate the drug, and 312.53(c)(1) requires a signed investigator statement (Form FDA-1572) before an investigator begins participating. For IITP itself, you confirm at checkout that you meet one route: you hold RARF or RARP (CASRAI) or equivalent knowledge of 21 CFR Parts 50, 54, 56, 312 and 812, or you have 2+ years of sponsor-side work on an investigator-initiated IND or IDE. There is no separate application.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →